Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill For Cannabinoid Therapies

Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies

ISRAEL: Intec Pharma, a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids contained in Cannabis sativa. “We’re excited about these encouraging results from our Read the full article…

Marijuana’s Promise Of Profit Remains Elusive (For Now)

Those trials are all ongoing, so investors will need to rely on past trial data to make judgments on whether or not the market demand for GW Pharma's medicine will justify the company's $1.27 billion market cap.

NEW YORK: Excitement surrounding medical marijuana led to a significant run-up in GW Pharmaceuticals‘ share price earlier this year, but based on the company’s recently announced quarterly and fiscal full-year earnings results, the promise of marijuana profit remains far off in the distance. Planning for the future That’s because GW Pharma has only one marketed marijuana derived therapy, Read the full article…

FDA Approves Clinical Trials For Cannabis-based Epilepsy Drug

On Oct.  4, at the NYU Langone Medical Center, Devinsky led a conference entitled, "Cannabidiols: Potential Use in Epilepsy & Other Neurological Disorders." During the affair, Devinsky and Cilio led a presentation on planned trials on CBD in children with treatment resistant epilepsy.

DISTRICT OF COLUMBIA: The U.S.  Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy.  The treatment, Epidiolex, is 98 percent purified cannabidiol ( CBD ) made by GW Pharmaceuticals based out of the U.K. There are around 60 known chemicals contained in cannabis called cannabinoids.  Tetrahydrocannabinol, also known Read the full article…